Claims for Patent: 9,642,851

Summary for Patent: 9,642,851

Title:	Indolinone derivative as tyrosine kinase inhibitor
Abstract:	The present invention relates to a compound represented by general formula (I), a method for preparing said compound, a pharmaceutical formulation containing said compound, and the use of said compound in manufacture of a medicament for treating or preventing the fibrous degeneration disease and treating the excessive proliferation disease: ##STR00001## wherein ring A, X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, a, b and n are defined as those in the description.
Inventor(s):	Lo; Hoyin (Jinan, CN), Wang; Aichen (Jinan, CN), Zhang; Qian (Jinan, CN)
Assignee:	KBP BioSciences Co., Ltd. (Jinan, Shandong Province, CN)
Application Number:	14/650,270
Patent Claims:	1. A compound represented by general formula (I), a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof: ##STR00259## wherein, X represents O or S; R.sub.1 represents H or a prodrug group thereof; R.sub.2, R.sub.4 and R.sub.5 each independently represent H; R.sub.3 represents carboxyl, C.sub.1-6alkyl-OC(O)--, C.sub.1-6alkyl-SC(O)--, 3-14-membered cycloalkyl-OC(O)--, or carbamoyl, which is unsubstituted or substituted by 1-3 groups represented by Q.sub.1; Q.sub.1 represents 6-14-membered aryl, or 3-14-membered cycloalkyl; R.sub.6 represents 6-14-membered aryl, 7-12-membered bridged ring group-C.sub.0-3alkyl, 7-12-membered spiro ring group-C.sub.0-3alkyl or 3-14-membered heterocyclylC.sub.0-3alkyl, which is unsubstituted or substituted by 1-3 groups represented by Q.sub.2, Q.sub.2 represents halogen, trifluoromethyl, C.sub.1-3alkyl, or C.sub.1-3alkyloxy; R.sub.7 represents H, C.sub.1-3alkyl, or 3-14-membered cycloalkyl; Ring A represents phenyl or 5-7-membered heterocyclyl; R.sub.8 represents formula (IIa), ##STR00260## wherein, R.sub.a, R.sub.b, R.sub.c and R.sub.d each independently represent H, R.sub.e represents C.sub.1-3alkyloxy, amino, C.sub.1-3alkylamino, di(C.sub.1-3alkyl)amino, di(C.sub.1-3alkyl)carbamoyl, phenylamino, phenyl, or 3-8-membered monocyclic heterocyclyl, the carbon atom on the 3-8-membered monocyclic heterocyclyl can be replaced with 1-3 groups selected from C(O), the C.sub.1-3alkyl and the 3-8-membered monocyclic heterocyclyl can be substituted by 1-3 groups as represented by Q.sub.3; Q.sub.3 represents hydroxyl or C.sub.1-3alkyl; R.sub.9 represents H; a represents 0 or 1; b represents 1 or 2; n represents 0, 1 or 2, when n is 2, the substituents represented by R.sub.9 can be identical or different; n.sub.1 represents 0 or 1; n.sub.2 represents 1; and n.sub.3 represents 1 or 2. 2. The compound of claim 1, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof: wherein, X represents O or S; R.sub.1 represents H or a prodrug group thereof; R.sub.2, R.sub.4 and R.sub.5 each independently represent H; R.sub.3 represents carboxyl, C.sub.1-3alkyl-OC(O)--, 3-8-membered monocyclic cycloalkylOC(O)--, or carbamoyl, which is unsubstituted or substituted by 1-3 groups represented by Q.sub.1, Q.sub.1 represents phenyl, or 3-6-membered cycloalkyl; R.sub.6 represents the following groups, which are unsubstituted or substituted by 1-3 groups represented by Q.sub.2: (1) 6-14 -membered aryl, or ##STR00261## ##STR00262## p represents 0, 1, 2 or 3, r represents 0, 1 or 2, s represents 0, 1 or 2, Q.sub.2 represents halogen, trifluoromethyl, C1-3alkyl, or C.sub.1-3alkyloxy; R.sub.7 represents H, C.sub.1-3alkyl, or 3-6-membered monocyclic cycloalkyl; Ring A represents phenyl, pyrrolyl, pyridyl, pyrimidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl; R.sub.8 represents formula (IIa) ##STR00263## wherein, R.sub.a, R.sub.b, R.sub.c and R.sub.d each independently represent H, R.sub.e represents C.sub.1-3alkyloxy, amino, C.sub.1-3alkylamino, di(C.sub.1-3alkyl)amino, di(C.sub.1-3alkyl)carbamoyl, phenylamino, phenyl or 5-7-membered monocyclic heterocyclyl, the carbon atom on the 5-7-membered monocyclic heterocyclyl can be replaced with 1-3 groups selected from C(O), the C.sub.1-3alkyl and the 5-7-membered monocyclic heterocyclyl can be substituted by 1-3 groups represented by Q.sub.3, Q.sub.3 represents hydroxyl or C.sub.1-3alkyl; R.sub.9 represents H; a represents 0 or 1; b represents 1 or 2; n represents 0, 1 or 2, when n is 2, the substituents represented by R.sub.9 can be identical or different; n.sub.1 represents 0 or 1; n.sub.2 represents 1; and n.sub.3 represents 1 or 2. 3. The compound of claim 2, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof: wherein, X represents O; R.sub.1 represents H; R.sub.2, R.sub.4 and R.sub.5 each independently represent H; R.sub.3 represents C.sub.1-3alkylOC(O)-- or carbamoyl; R.sub.6 represents the following groups, which are unsubstituted or substituted by 1-3 groups represented by Q.sub.2: (1) phenyl, or ##STR00264## ##STR00265## p represents 0, 1, 2 or 3, r represents 1, s represents 1, Q.sub.2 represents halogen, trifluoromethyl, C.sub.1-3alkyl, or C.sub.1-3 alkyloxy; R.sub.7 represents H or 3-5-membered monocyclic cycloalkyl; Ring A represents phenyl or pyridyl; R.sub.8 represents formula (IIa) ##STR00266## wherein, R.sub.a, R.sub.b, R.sub.c and R.sub.d each independently represent H, R.sub.e represents C.sub.1-3alkyloxy, amino, C.sub.1-3alkylamino, di(C.sub.1-3alkyl)amino, di(C.sub.1-3alkyl)carbamoyl, phenylamino, phenyl or 5-7-membered monocyclic heterocyclyl, the carbon atom on the 5-7-membered monocyclic heterocyclyl can be replaced with 1-3 groups selected from C(O), the C.sub.1-3alkyl and the 5-7-membered monocyclic heterocyclyl can be substituted by 1-3 groups represented by Q.sub.3, Q.sub.3 represents, hydroxy, or methyl; R.sub.9 represents H; a represents 0 or 1; b represents 1 or 2; n represents 0 or 1; n.sub.1 represents 0 or 1; n.sub.2 represents 1; and n.sub.3 represents 1 or 2. 4. The compound of claim 3, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, the compound has a structure represented by the below general formula (II): ##STR00267## wherein, X represents O; R.sub.1 represents H; R.sub.2, R.sub.4 and R.sub.5 each independently represent H; R.sub.3 represents CH.sub.3OC(O)--, CH.sub.3CH.sub.2OC(O)--, (CH.sub.3).sub.2CHOC(O)-- or NH.sub.3C(O)--; R.sub.6 represents the following groups, which are unsubstituted or substituted by 1-3 groups represented by Q.sub.2: phenyl, tetrahydrofuryl, tetrahydropyranyl, ##STR00268## Q.sub.2 represents halogen, trifluoromethyl, methyl, or methoxy; R.sub.7 represents H or cyclopropyl; R.sub.8 represents formula (IIb) ##STR00269## wherein, R.sub.e represents C.sub.1-3alkyloxy, di(C.sub.1-3alkyl)amino, di(C.sub.1-3alkyl)carbamoyl, phenylamino, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl or morpholinyl, said pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl, and morpholinyl can be substituted by 1-3 groups represented by Q.sub.3, Q.sub.3 represents halogen, or methyl; R.sub.9 represents H; a represents 0 or 1; b represents 1 or 2; n represents 0; and n.sub.3 represents 1 or 2. 5. The compound of claim 4, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof: wherein, X represents O; R.sub.1 represents H; R.sub.2, R.sub.4 and R.sub.5 each independently represent H; R.sub.3 represents CH.sub.3OC(O)--, or CH.sub.3CH.sub.2OC(O)--; R.sub.6 represents the following groups, which are unsubstittued or substituted by 1-3 groups selected from halogen, trifluoromethyl and methoxy: ##STR00270## phenyl, tetrahydrofuryl, tetrahydropyranyl or R.sub.7 represents H or cyclopropyl; R.sub.8 represents formula (IIb) ##STR00271## wherein R.sub.e represents dimethylamino, dimethylcarbamoyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl or morpholinyl, said pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl, and morpholinyl can be substituted by 1-2 groups selected from Q.sub.3, Q.sub.3 represents methyl; R.sub.9 represents H; a represents 0; b represents 2; n represents 0; and n.sub.3 represents 1 or 2. 6. The compound of claim 5, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof: wherein, X represents O; R.sub.1 represents H; R.sub.2, R.sub.4 and R.sub.5 each independently represent H; R.sub.3 represents CH.sub.3OC(O)--, or CH.sub.3CH.sub.2OC(O)--; R.sub.6 represents phenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, or 4-methoxyphenyl; R.sub.7 represents H; R.sub.8 represents formula (IIb) ##STR00272## wherein R.sub.e represents dimethylamino, dimethylcarbamoyl, pyrazolyl, triazolyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, N-methylpiperidinyl, 4-hydroxypiperidinyl, N-methylpiperazinyl, morpholinyl, or 3,5-dimethylmorpholinyl; R.sub.9 represents H; a represents 0; b represents 2; n represents 0; and n.sub.3 represents 1 or 2. 7. A compound, or a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, wherein the compound is selected from the group consisting of: ##STR00273## ##STR00274## ##STR00275## ##STR00276## ##STR00277## ##STR00278## ##STR00279## ##STR00280## ##STR00281## ##STR00282## ##STR00283## ##STR00284## ##STR00285## ##STR00286## ##STR00287## ##STR00288## ##STR00289## 8. A compound, or a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, wherein the compound is selected from the group consisting of: ##STR00290## ##STR00291## ##STR00292## ##STR00293## ##STR00294## ##STR00295## ##STR00296## ##STR00297## ##STR00298## ##STR00299## ##STR00300## ##STR00301## ##STR00302## ##STR00303## ##STR00304## 9. A method for preparing a compound according to claim 1, or a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, wherein said method comprises reacting a compound represented by formula (III) with a compound represented by formula (IV) to produce the compound represented by formula (I), ##STR00305## 10. The compound according to claim 1, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, wherein said salt is selected from the group consisting of hydrochloride, sulfate, esilate, mesilate, maleate, tosilate, benzenesulfonate, and oxalate. 11. A pharmaceutical composition comprising the compound according to claim 1, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, and optionally one or more pharmaceutically acceptable carriers. 12. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition further comprises a second therapeutical agent selected from an antineoplastic agent or an immunosuppressive agent, wherein the second therapeutical agent is selected from antimetabolites, selected from the group consisting of capecitabine, and gemcitabine, or combinations thereof; growth factor inhibitors, selected from the group consisting of gefitinib, lapatinib, pazopanib, and imatinib, or combinations thereof; antibodies, selected from the group consisting of herceptin, and bevacizumab, or combinations thereof; mitotic inhibitors, selected from the group consisting of paclitaxel, vinorelbine, docetaxel, and doxorubicin, or combinations thereof; antineoplastic hormones, selected from the group consisting of letrozole, tamoxifen, and fulvestrant, or combinations thereof; alkylating agents, selected from the group consisting of cyclophosphamide, and carmustine, or combinations thereof; metallic platinums, selected from the group consisting of carboplatin, cisplatin, and oxaliplatin, or combinations thereof; topoismerase inhibitors; or immunosuppressive agents, selected from the group consisting of everolimus, anticholinergic agents, .beta.choline mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK.sub.1 antagonists, LTD4 antagonists, EGFR inhibitors, and endothelin antagonists, or combinations thereof. 13. A pharmaceutical formulation, wherein said pharmaceutical formulation comprises the compound according to claim 1, a pharmaceutically acceptable salt, a deuteride or a stereoisomer thereof, and one or more pharmaceutically acceptable carriers, wherein said pharmaceutical formulation is in any pharmaceutically acceptable dosage. 14. A method of treating at least one of fibrous degeneration disease, treating excessive proliferation disease, inhibiting the angiogenesis and reducing vascular permeability comprising the step of: administering the compound according to claim 1, or a pharmaceutically acceptable salt, a deuteride, or a stereoisomer thereof, wherein the fibrous degeneration disease is atleast one of fibrous degeneration and remodeling of pulmonary tissue in chronic obstructive pulmonary disease; fibrous degeneration and remodeling of pulmonary tissue in chronic bronchitis; fibrous degeneration and remodeling of pulmonary tissue in emphysema; pulmonary fibrous degeneration and pulmonary disease with fibrosis components; fibrous degeneration and remodeling in asthma; fibrous degeneration in rheumatoid arthritis; virus-induced hepatic cirrhosis; radiation-induced fibrous degeneration; postangioplasty restenosis; chronic glomerulonephritis; renal fibrous degeneration in a cyclosporin-administrated patient and hypertension-induced renal fibrous degeneration; and skin disease having fibrosis components and over cicatrization; wherein the excessive proliferation disease is at least one of cancer and non-carcinomatous disease; the cancer is selected from the group consisting of cerebroma, pulmonary carcinoma, nonsmall cell pulmonary carcinoma, squamous cell carcinoma, bladder carcinoma, gastric carcinoma, ovarian carcinoma, peritoneal carcinoma, pancreatic carcinoma, breast carcinoma, head and neck carcinoma, uterocervical carcinoma, endometrial carcinoma, colorectal carcinoma, hepatoma, renal carcinoma, adenocarcinoma of esophagus, esophageal squamous cell carcinoma, solid tumor, non-Hodgkin lymphoma, central nervous system neuroplasm selected from glioma, glioblastoma multiforme, glioma sarcomatosum, prostatic carcinoma, and thyroid carcinoma, or combinations thereof; non-carcinomatous disease selected from the group consisting of benign skin and prostate hyperplasia, or combinations thereof. 15. A method of treating at least one of fibrous degeneration disease, treating excessive proliferation disease, inhibiting the angiogenesis and reducing vascular permeability comprising the step of: administering the compound according to claim 1, or a pharmaceutically acceptable salt, a deuteride, or a stereoisomer thereof, wherein pulmonary fibrous degeneration and the pulmonary disease having fibrous degeneration components is atleast one of idiopathic pulmonary fibrosis degeneration, giant cell interstitial pneumonia, sarcoidosis, cystic fibrous degeneration, respiratory distress syndrome, drug-induced pulmonary fibrous degeneration, granulomatosis, silicosis, asbestosis, systemic sclerosis, virus-induced hepatic cirrhosis, and skin disease having fibrous degeneration components selected from the group consisting of scleroderma, and systemic lupus erythematosus, or combinations thereof.

Details for Patent 9,642,851

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-12-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-12-06
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-12-06